CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.67B, above the global median of $1.18B
- PositionOperating margin is 40.6%, higher than 95% of its Biotechnology peers (median -38%)
- Interpretations12 currently firing — 12
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.31TKRW1.67B · vs all stocks (USD)
Trailing P/E
16.38xvs Biotechnology peers
Revenue (TTM)
479.57BKRW346.15M · vs all stocks (USD)
Profit Margin
32.94%vs Biotechnology peers
Beta
0.5640xvs all stocks
52-Week Change
-31.08%vs all stocks
Market Capitalization
2.31TKRW1.67B · vs all stocks (USD)
Enterprise Value
1.77TKRW1.28B · vs all stocks (USD)
Trailing P/E
16.38xvs Biotechnology peers
Forward P/E
12.10xvs Biotechnology peers
PEG Ratio
0.8014xvs Biotechnology peers
Price to Sales (TTM)
4.82xvs Biotechnology peers
Price to Book (MRQ)
2.13xvs Biotechnology peers
Enterprise to Revenue
3.68xvs Biotechnology peers
Enterprise to EBITDA
7.68xvs Biotechnology peers
Gross Margin
76.69%vs Biotechnology peers
Profit Margin
32.94%vs Biotechnology peers
Operating Margin
40.63%vs Biotechnology peers
Return on Assets (TTM)
11.87%vs Biotechnology peers
Return on Equity (TTM)
16.53%vs Biotechnology peers
Revenue (TTM)
479.57BKRW346.15M · vs all stocks (USD)
Revenue per Share (TTM)
44.56KKRWUpdated Sep 20, 2026Quarterly Revenue Growth
25.10%vs Biotechnology peers
Gross Profit (TTM)
373.69BKRW269.73M · vs all stocks (USD)
EBITDA (TTM)
250.08BKRW180.51M · vs all stocks (USD)
Net Income (TTM)
157.98BKRW114.03M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
19.00%vs Biotechnology peers
Operating Cash Flow (TTM)
181.45BKRW130.97M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
72.74BKRW52.50M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
29.90BKRWFY2025 · Dec 31, 2025Revenue
425.11BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
91.63BKRWFY2025 · Dec 31, 2025Gross Profit
333.48BKRWFY2025 · Dec 31, 2025Operating Income
200.85BKRW144.97M · vs all stocks (USD)
Pre-tax Income
196.75BKRWFY2025 · Dec 31, 2025Income Tax Expense
49.78BKRWFY2025 · Dec 31, 2025Net Income
146.97BKRWFY2025 · Dec 31, 2025EBIT
197.88BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
230.21BKRWFY2025 · Dec 31, 2025Research & Development
11.70BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
63.86BKRWFY2025 · Dec 31, 2025Other Operating Expenses
395.61MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
12.64BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
1.13BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
146.97BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-6.10BKRWFY2025 · Dec 31, 2025Operating Cash Flow
105.10BKRWFY2025 · Dec 31, 2025Free Cash Flow
91.87BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
209.70BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
146.97BKRWFY2025 · Dec 31, 2025Stock-based Compensation
7.42BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-9.89BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-22.89BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-16.52BKRWFY2025 · Dec 31, 2025Capital Expenditures
-13.23BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-16.13BKRWFY2025 · Dec 31, 2025Purchase of Investments
-565.77BKRWFY2025 · Dec 31, 2025Sale of Investments
546.67BKRWFY2025 · Dec 31, 2025Other Investing Activity
-159.78MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-32.50BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-1.32BKRWFY2025 · Dec 31, 2025Other Financing Charges
-23.87BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-19.23BKRWFY2025 · Dec 31, 2025Shares Outstanding
10.80MSharesUpdated Sep 20, 2026Float Shares
5.24MSharesUpdated Sep 20, 2026% Held by Insiders
42.79%vs all stocks
% Held by Institutions
23.90%vs all stocks
Total Cash (MRQ)
606.19BKRW437.55M · vs all stocks (USD)
Total Cash per Share (MRQ)
56.11KKRWUpdated Sep 20, 2026Total Debt (MRQ)
28.31BKRW20.44M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0260xvs Biotechnology peers
Current Ratio (MRQ)
7.55xvs Biotechnology peers
Book Value per Share (MRQ)
100.70KKRWUpdated Sep 20, 2026Total Assets
1.08TKRW777.26M · vs all stocks (USD)
Total Current Assets
679.37BKRWFY2025 · Dec 31, 2025Total Liabilities
96.68BKRWFY2025 · Dec 31, 2025Total Non-current Assets
397.47BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
3.63BKRWFY2025 · Dec 31, 2025Total Current Liabilities
93.05BKRWFY2025 · Dec 31, 2025Cash
209.70BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
209.70BKRWFY2025 · Dec 31, 2025Other Short-term Investments
329.07BKRWFY2025 · Dec 31, 2025Accounts Receivable
74.99BKRWFY2025 · Dec 31, 2025Inventory
55.85BKRWFY2025 · Dec 31, 2025Accounts Payable
5.99BKRWFY2025 · Dec 31, 2025Short-term Debt
28.38BKRWFY2025 · Dec 31, 2025Other Current Liabilities
520.94MKRWFY2025 · Dec 31, 2025Long-term Debt
751.25MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
400.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
6.59BKRWFY2025 · Dec 31, 2025Retained Earnings
1.16TKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
980.16BKRW707.48M · vs all stocks (USD)
Treasury Stock
268.81BKRWFY2025 · Dec 31, 202552-Week Low
208.50KKRWUpdated Sep 20, 202652-Week High
313.50KKRWUpdated Sep 20, 202652-Week Change
-31.08%vs all stocks
Beta
0.5640xvs all stocks
50-Day MA
244.02KKRWUpdated Sep 20, 2026200-Day MA
249.73KKRWUpdated Sep 20, 2026Avg 10-Day Volume
42.51KSharesUpdated Sep 20, 2026Avg 30-Day Volume
43.89KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
12.82KKRWUpdated Sep 20, 202612 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
Down-Close Streak With Profitability
A run of down weeks on a company profitable three years running and funded by equity.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 40.6%, higher than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: 0.41Industry median: -0.38Industry P95: 0.40Peers compared: 260
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.67B, above the global median of $1.18BNotable
Market cap (USD): 1,668,732,659.438Global Median: 1,180,223,658.953
Levered free cash flow is $52.5M, above the global median of $18.73MNotable
Levered free cash flow (USD): 52,504,562.59Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Absci Corporation
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Shyndec Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eton Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Classys Inc.
12 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginDown-Close Streak With ProfitabilityIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Equity
Computer Age Management Services Ltd.
12 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginDown-Close Streak With ProfitabilityIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Equity
United States Lime & Minerals Inc.
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginDown-Close Streak With ProfitabilityIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels